Abstract
Circulating T lymphocytes of patients with prostate cancer have been reported to have functional deficits, including low or absent ζ-chain expression. To determine whether these functional impairments could be reversed by prostate specific antigen-based vaccination therapy, 10 patients treated with recombinant human prostate specific antigen plus GM-CSF and eight others receiving prostate specific antigen plus oil emulsion in two pilot clinical trials were evaluated prior to and after vaccination for several immunologic end points, including ζ-chain expression and cytokine production by circulating T cells as well as the frequency of T cells able to respond to prostate specific antigen in ELISPOT assays. The flow cytometry assay for ζ-chain expression was standardized to allow for a reliable comparison of pre- vs post-vaccination samples. Prior to therapy, the patients were found to have significantly lower ζ-chain expression in circulating CD3+ cells and a higher percentage of ζ-chain negative CD3+ and CD4+ cells than normal donors. The patients' peripheral blood mononuclear cells spontaneously produced more IL-10 ex vivo than those of normal controls. After vaccination, recovery of ζ-chain expression was observed in 50% of patients in both clinical trials. Also, spontaneous IL-10 secretion by peripheral blood mononuclear cells decreased following immunotherapy in patients treated with prostate specific antigen and GM-CSF. The frequency of prostate specific antigen-reactive T cells was detectable in 7 out of 18 patients vs 4 out of 18 patients prior to vaccination. Only one of 18 patients was a clinical responder. The vaccine had stimulatory effects on the patients' immune system, but post-vaccine immune recovery could not be correlated to progression-free survival in this small cohort of patients with prostate cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Alving, CR, Shichijo, S, Mattsby-Baltzer, I, Richards, RL, Wassef, NM (1993) Preparation and use of liposomes in immunological studies. In: Liposomes Technology Gregoriadis G (ed.), pp 317–343, Boca Raton: CRC Press
Asai, T, Storkus, WJ, Whiteside, TL (2000) Evaluation of the modified ELISPOT assay for interferon-γ production in monitoring of cancer patients receiving anti-tumour vaccines. CDLI 7: 145–154
Bukowski, RM, Rayman, P, Uzzo, R, Bloom, T, Sandstrom, K, Peereboom, D, Olencki, T, Budd, GT, McLain, D, Elson, P, Novick A, Finke, JH (1998) Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy. Clin Cancer Res 4: 2337–2347
Cardi, G, Heaney, JA, Schned, AR, Phillips, DM, Branda, MT, Ernstoff, MS (1997) T-cell receptor zeta-chain expression on tumor-infiltrating lymphocytes from renal cell carcinoma. Cancer Res 57: 3517–3519
Deakin, AM, Singh K, Crowe JS, Ellis JH, Dalgleish, A, Leicester, RJ, Finlayson, CJ, Miles, WF, Life, PF (1999) A lack of evidence for down-modulation of CD3 zeta expression in colorectal carcinoma and pregnancy using multiple detection methods. Clin Exp Immunol 118: 197–204
De Vita, F, Orditura, M, Galizia, G, Romano, C, Lieto, E, Iodice, P, Tuccillo, C, Catalano, G (2000) Serum interleukin-10 is an independent prognostic factor in advanced solid tumors. Oncol Rep 7: 357–361
Dworacki, G, Meidenbauer, N, Kuss, I, Hoffmann, TK, Gooding, W, Lotze, M, Whiteside, TL (2001) Decreased ζ-chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 7: 947–957
Gastman, BR, Johnson, DE, Whiteside, TL, Rabinowich, H (1999) Caspase-mediated degradation of T-cell receptor zeta-chain. Cancer Res 59: 1422–1427
Gratama, JW, Zea, AH, Bolhuis, RL, Ochoa, AC (1999) Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy. Cancer Immunol Immunother 48: 263–269
Healy, CG, Simons, JW, Carducci, MA, DeWeese, TL, Bartkowski, M, Tong, KP, Bolton, WE (1998) Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 32: 109–119
Horiguchi, S, Petersson, M, Nakazawa, T, Kanda, M, Zea, AH, Ochoa, AC, Kiessling, R (1999) Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. Cancer Res 15:59: 2950–2956
Kono, K, Salazar-Onfray, F, Petersson, M, Hanson, J, Masucci, G, Wassesman, K, Nakazawa, T, Anderson, P, Kiessling, R (1996) Hydrogen peroxide secreted by tumor-derived macrophages down modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediatd cytotoxicity. Eur J Immunol 26: 1308–1313
Kono, K, Ichihara, F, Iizuka, H, Sekikawa, T, Matsumoto, Y (1998) Expression of signal transducing T-cell receptor zeta molecules after adoptive immunotherapy in patients with gastric and colon cancer. Int J Cancer 29: 301–305
Kuss, I, Saito, T, Johnson, JT, Whiteside, TL (1999) Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res 5: 329–334
Lewis, JJ, Janetzki, S, Schaed, S, Panageas, KS, Wang S, Williams, L, Meyers, M, Butterworth, L, Livingston, PO, Chapman, PB, Houghton, AN (2000) Evaluation of CD8+ T-cell frequencies by the ELISPOT assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer 87: 391–398
Lodge, PA, Jones, LA, Bader, RA, Murphy, GP, Salgaller, ML (2000) Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial. Cancer Res 60: 829–833
Lundwall, A, Lilja, H (1987) Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 214: 317–122
Maccalli, C, Pisarra, P, Vegetti, C, Sensi, M, Parmiani, G, Anichini, A (1999) Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions. J Immunol 15: 6912–6923
Matsuda, M, Petersson, M, Lenkei R, Taupin, JL, Magnusson, I, Mellstedt, H, Anderson, P, Kiessling, R (1995) Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 61: 765–772
Meidenbauer, N, Harris, DT, Spitler, LE, Whiteside, TL (2000) Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 43: 88–100
Moore, KW, O'Garra, A, de Waal Malefyt R, Vieira P, Mosmann, TR (1993) Interleukin-10. Annu Rev Immunol 11: 165–190
Murphy, GP, Snow P, Simmons, SJ, Tjoa, BA, Rogers, MK, Brandt J, Healy, CG, Bolton, WE, Rodbold, D (2000) Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patients. Prostate 42: 67–72
Rabinowich, H, Banks, M, Reichert, TE, Logan, TF, Kirkwood, JM, Whiteside, TL (1996) Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res 2: 1263–1274
Rabinowich, H, Reichert, TE, Kashii Y, Gastman, BR, Bell, MC, Whiteside, TL (1998) Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells: Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest 101: 2579–2588
Reichert, TE, Day, R, Wagner, EM, Whiteside, TL (1998) Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 58: 5344–5347
Reichert, TE, Scheuer, C, Wagner, EM, Whiteside, TL (2000) Signal transduction abnormalities, apoptosis and reduced proliferation of lymphocytes in the peripheral blood and at the tumor site of patients with oral carcinoma. 5th Int Conf on Head and Neck Cancer, San Francisco, CA (Abstract)
Schmielau, J, Finn, OJ (2001) Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 61: 4756–4760
Tartour, E, Latour, S, Mathiot, C, Thiounn, N, Mosseri, V, Joyeux, I, D'Enghien, CD, Lee, R, Debre, B, Fridman, WH (1995) Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL)derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer 63: 205–212
Taylor, DD, Bender, DP, Taylor i.ek Ger, Stanson J, Whiteside, TL (2001) Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients. Br J Cancer 84: 1624–1629
Wassef, NM, Alving, CR, Richards, RL (1994) Liposomes as carriers for vaccines. Immunomethods 4: 217–222
Whiteside, TL (1999) Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 48: 346–352
Zea, AH, Curti, BD, Longo, DL, Alvord, WG, Strobl, SL, Mizoguchi, H, Creekmore, SP, O'Shea, JJ, Powers, GC, Urba, WJ (1995) Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1: 1327–1335
Acknowledgements
Supported in part by the NIH Grants PO-1 DE 12321 (TL Whiteside) and RO1-CA 3513 (TL Whiteside).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Meidenbauer, N., Gooding, W., Spitler, L. et al. Recovery of ζ-chain expression and changes in spontaneous IL-10 production after PSA-based vaccines in patients with prostate cancer. Br J Cancer 86, 168–178 (2002). https://doi.org/10.1038/sj.bjc.6600039
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6600039